Direct long-acting antibodies: updating the language of RSV prevention to reflect the evolution of mAbs.

Pier Luigi LopalcoSusanna EspositoFederico Martinón-Torresnull nullGiovanni Checcucci LisiKocfa Chung-DelgadoBrad DavidsonStephanie EvansAmit PatelClaire FellinghamBen PoundsCharlotte HarrisTapas Mukherjee

Published in: Journal of preventive medicine and hygiene (2024)

This change will more accurately convey the specific mode of action of a mAb in infants, and how it could impact the prevention of communicable diseases: this class of mAbs is not an active treatment, but rather will offer direct and rapid protection lasting at least 5 months.

Keyphrases

working memory
autism spectrum disorder
respiratory syncytial virus
combination therapy
respiratory tract
replacement therapy